Shortage of trials is biggest barrier for patients
Call for ‘physician champions’
Dr Cathy Kelly, Consultant Medical Oncologist at the Mater Hospital,one of the study's authors.
A study by the Medical Oncology Department at the Mater Hospital, Dublin, in association with Cancer Trials Ireland, has found that the biggest barrier to patients participating in cancer trials is the availability of suitable cancer trials.
The study found that there was no cancer trial option available for the majority of patients (71%) studied because the trials that were open did not meet their specific cancer type, the stage of their disease and their line of treatment.
Participants talk about cancer trials
Cancer Trials Ireland has launched a series of 6 shorts videos which involve people talking directly about their experience taking part in a cancer trial.
The videos are available to view at Cancer Trials Ireland’s website. http://www.cancertrials.ie/about-us/why-cancer-trials1
European breast cancer trial opens in Ireland
Cancer Trials Ireland has opened the Irish arm of a European breast cancer trial to test the effectiveness of a new combination of drugs as a first line treatment for advanced breast cancer.
Known as The FLIPPER Study, the trial is sponsored by GEICAM, the Spanish Breast Cancer Group, and will involve 190 patients across Europe, with 40 from Ireland.
The trial will investigate the added benefit of combining the new drug palbociclib with an existing drug fulvestrant. Fulvestrant is currently used to treat postmenopausal women with hormone receptor (HR)-positive advanced breast cancer.
Answers to questions you may have about Cancer Trials….Click here
Cancer Trials Ireland opens new breast cancer trial
Cancer Trials Ireland has today (Monday, 27 June 2016) announced that it has opened a cancer trial to test a new treatment for patients with advanced breast cancer which has not responded to currently available treatments.
The trial will test for the first time the use of the new drug copanlisib in combination with trastuzumab to treat advanced HER2-positive (HER2+) breast cancer which has progressed or recurred in patients during or following standard anti-HER2 treatment.
It is expected that up 34 patients will take part in the trial which will be conducted over the next 2-3 years in Beaumont Hospital in Dublin, St Vincent’s University Hospital in Dublin, St. James’s Hospital in Dublin, University Hospital Galway and Cork University Hospital at a cost of approximately 750,000 euro.
Cancer Trials Ireland has been conducting cancer trials with local and global pharmaceutical partners for many years.
We have a wealth of experience and expertise to deliver cancer trials success.
If you would like to find out more about how we can work together please contact:
- Business Development Manager
- Email: email@example.com